Stability indicating RP-HPLC method for determination of valsartan in pure and pharmaceutical formulation

E-Journal of Chemistry

Volumn 7, Issue 1, 2010, Pages 246-252

  Patro, S K ^a   Kanungo, S K ^a   Patro, V J ^b   Choudhury, N S K ^c  

^a INSTITUTE OF PHARMACY AND TECHNOLOGY   (India)

^b A P C Ray Memorial Cancer Chemotherapeutic Research Unit   (India)

^c S C B MEDICAL COLLEGE   (India)

Author keywords

Degradation studies; RP HPLC; Valsartan

Indexed keywords

EID: 77649277517     PISSN: None     EISSN: 09734945     Source Type: Journal    
DOI: 10.1155/2010/487197     Document Type: Article

References (9)

1. Rockville M D, United States Pharmacopoeia; 25th Edn., United States Pharmacopoeial Convention Inc, 2002, 2150.
2. th Edn; Merk & Co, Inc., Whitehouse Station, NJ, 1996, 1691.
3. Crisscione L, Gasparo M D, Buhlamayer P, Whitebread S, Ramjoune, and Wood J Br J Pharmacol., 1993, 110, 761-771.
4. Criscione L, Bradlely W A, Buhlmayer P, Whitebread S, Glazer R P, Lloyd P, Mueller M and Gasparo M D, Drug Rev., 1995, 13, 230-250.
5. Thurmann P V, Expert Opin Pharmacother., 2000, 1, 337-350.
6. Satana E, Altinay S, Goeger S A and Ozkan Z Sanmurk, J Pharm Biomed Anal., 2001, 25, 1009-1013.
7. Tatar S and Saglik S, J Pharm Biomed Anal., 2002, 30, 371-375.
8. nd Edn., Marcel Dekker, New York, 2008, 358.
9. nd Edn., Wiley-interscience Publication, John Wiley & Sons, Inc, 1997, 709.